Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Published:2017-04 Issue:4 Volume:18 Page:500-514
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ladenstein Ruth,Pötschger Ulrike,Pearson Andrew D J,Brock Penelope,Luksch Roberto,Castel Victoria,Yaniv Isaac,Papadakis Vassilios,Laureys Geneviève,Malis Josef,Balwierz Walentyna,Ruud Ellen,Kogner Per,Schroeder Henrik,de Lacerda Ana Forjaz,Beck-Popovic Maja,Bician Pavel,Garami Miklós,Trahair Toby,Canete Adela,Ambros Peter F,Holmes Keith,Gaze Mark,Schreier Günter,Garaventa Alberto,Vassal Gilles,Michon Jean,Valteau-Couanet Dominique

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group;London;J Clin Oncol,2005

2. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas;Seeger;N Engl J Med,1985

3. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy;Valteau-Couanet;Pediatr Blood Cancer,2014

4. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study;Matthay;J Clin Oncol,2009

5. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial;Pearson;Lancet Oncol,2008

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of plasma MicroRNA-21, MicroRNA-155 and circulating monocytes plasticity to childhood neuroblastoma development and induction treatment outcome;Pathology - Research and Practice;2024-02

2. Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN;NAR Cancer;2024-01-09

3. Identification of a ferroptosis-related gene signature for the prognosis of pediatric neuroblastoma;2023-12-29

4. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition;Proceedings of the National Academy of Sciences;2023-12-28

5. The Impact of 131I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma;Children;2023-12-18